Please provide your email address to receive an email when new articles are posted on . ATLANTA — The standard approach of maintaining hematocrit levels less than 45% in patients with polycythemia ...

Please provide your email address to receive an email when new articles are posted on . High hematocrit levels were observed among 8.4% of adults receiving gender-confirming testosterone therapy.

Atlanta, GA - Maintaining a lower hematocrit (HCT) can help reduce the risk of cardiovascular death in patients with polycythemia vera, according to the results of CYTO-PV [1]. Those who had an HCT of ...

Cause of admission found to affect risk. SAN FRANCISCO—Dialysis patients hospitalized for infection, GI bleeding, or a major surgical procedure may experience a significant decline in hematocrit (Hct) ...

Use of dried blood or dried matrix spotting for assessment of hematocrit has become a popular laboratory method. However, the procedure may adversely affect the hematocrit values and thus interfere ...

SAN DIEGO -- A novel therapy for polycythemia vera (PCV) maintained stable hematocrit levels for as long as 2.5 years and significantly reduced use of phlebotomy, a small randomized trial showed. The ...

Credit: Thinkstock. The risk of hematocrit elevation may depend on testosterone therapy's route of administration, according to investigators. A rise in hematocrit levels occurs with 4 months of ...

According to Ira Zackon, MD, a hematologist-oncologist and senior medical director at Ontada, a retrospective study of over ...

Medically reviewed by Oliver Eng, MDKey TakeawaysBlood cancers like leukemia hinder the production of red blood cells, causing anemia.Kidney cancer can disrupt red blood cell production.Cancer ...

ATLANTA -- Maintaining patients with polycythemia vera at hematocrit levels below 45% reduced thrombotic complications without increasing rates of other serious adverse events compared with a higher ...

December 8, 2012 — Atlanta, GA — Maintaining a lower hematocrit (HCT) can help lower the risk for cardiovascular (CV) death in patients with polycythemia vera, according to the results of a new study.